Agilis Robotics Unveiled Cost-Effective Endoluminal Surgery Solutions

With significant funding and successful animal studies, Agilis Robotics prepares for groundbreaking first-in-human trials in 2024.

Agilis Robotics is at the forefront of revolutionizing “incisionless” endoluminal surgery through its development of highly miniaturized, flexible robotic instruments. These innovations allow surgeons to perform precise tissue resection procedures within natural orifices with unparalleled dexterity, especially in complex anatomies. 

The technology is compatible with standard endoscopes, such as colonoscopes and cystoscopes, already in use at hospitals and clinics, thereby capitalizing on existing endoscopic skills, reducing the learning curve and enhancing cost-efficiency. The versatility of these robotic instruments opens new avenues in endoluminal surgery across various medical fields, including gastrointestinal (GI), urinary, throat and gynecological procedures.

Cost-effective surgical system

Agilis Robotics’ system comprises a primary cart, a compact control console and single-use robotic arms, combining performance with sterility. This system is priced at less than 20% of existing robotic surgical systems, offering medical institutions a more affordable solution with the potential for higher profitability.

Meeting global demand for endoluminal surgeries

The rising global demand for endoluminal surgeries, fueled by increased cancer screening and early-stage tumor detection, places Agilis Robotics in a key position to meet the needs of the expanding market. With over 3.5 million new cases of GI cancer and 690,000 cases of bladder cancer diagnosed annually worldwide, the company’s innovations could significantly impact early-stage treatment effectiveness, procedure duration and recurrence rates.

Development and regulatory milestones

Originating from The University of Hong Kong, Agilis Robotics has secured over HK$90 million in funding from private investors, aimed at further development and clinical trial preparation. The company has conducted six live animal studies in Hong Kong and Shenzhen, showing the system’s precision, safety and efficacy. Plans for first-in-human trials are set for the first half of 2024, with ongoing preparations for regulatory submissions to the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA), a crucial step towards bringing their products to market.

Strategic financial outlook

Hui Ka-Ming, the company’s CFO, with a background in investment and biotech, notes the potential for success in the market, drawing parallels with “Chapter 18A” listed companies on the HKEX. Agilis Robotics focuses on cost-effectiveness, marketability and understanding market potential, ensuring a promising venture for both investors and healthcare institutions.

Also read: 

Header Image from Freepik

Press release link:


Share on facebook
Share on twitter
Share on linkedin
Share on email


What Are Altcoins and Is It Safe to Invest in These Cryptocurrencies?

In the crypto world, while Bitcoin continues to dominate headlines, there’s a growing interest in alternative cryptocurrencies, known as “altcoins”. Recent developments, such as Ethereum’s significant Shanghai upgrade and the U.S. Securities and Exchange Commission’s approval of Bitcoin ETFs, have spotlighted these innovative Bitcoin alternatives. Altcoins like Ethereum, Binance Coin and newcomers are carving out their own niches and pushing the boundaries of what cryptocurrencies can do.